Castle Creek Pharmaceutical LLC
http://www.castlecreekpharma.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Castle Creek Pharmaceutical LLC
US FDA’s Botanical Drugs Guidance Will See Rare Outing For Amryt’s Filsuvez NDA
Amryt’s birch bark extract oleogel-S10 for Epidermolysis Bullosa patients might become only the third botanical drug to clear the FDA.
Butterfly Skin Therapy Pipeline Primed For Transformation
No drugs are approved for epidermolysis bullosa and children with so-called butterfly skin are currently treated by cleaning open wounds and bandaging them. This could soon change.
Amryt Flies As Butterfly Skin Therapy Hits Late-Stage Goal
Filsuvez has the potential to become the first treatment approved for epidermolysis bullosa, a rare genetic condition where skin can tear and blister at even the slightest touch.
Finance Watch: iTeos, Pandion And Aspen Show COVID-19 Hasn’t Slowed VC Deals Yet
Aspen Neuroscience, Pandion and iTeos raised $70m, $80m and $125m, respectively. Also, Glide Healthcare closed a €416m ($450m) fund; ElevateBio, Kallyope and SutroVax reveal VC mega-rounds; and Dragonfly adds new funding to its partnering proceeds.
Company Information
- Industry
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
- Other Names / Subsidiaries
-
- Fibrocell Science, Inc.
- Paragon Biosciences